SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma reported Q2 2026 product revenue of €315M (+105% YoY),…

Ascendis Pharma · PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET

Ascendis Pharma reported Q2 2026 product revenue of €315M (+105% YoY), driven by YORVIPATH (€252M) and SKYTROFA (€55M), and achieved its first-ever operating profit of €220M (65% margin). The company also settled all $575M in convertible notes, converting them to equity, and reported non-IFRS diluted EPS of €0.90, which is in line with the Street consensus of $0.77 (€0.71), a modest beat. The strong top-line growth and profitability inflection are the key drivers, but the GAAP EPS of €2.83 includes a one-time €158M PRV sale and a €704M deferred tax asset recognition, masking underlying operating leverage.

  • Q2 2026 total revenue €339M vs €158M YoY (+115%)
  • Product revenue €315M, +105% YoY, driven by YORVIPATH €252M (+145% YoY)
  • First-ever operating profit of €220M (65% margin) vs operating loss of €53M YoY
  • Non-IFRS operating profit €92M (27% margin) vs non-IFRS operating loss of €23M YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access